Page last updated: 2024-11-02

pentobarbital and Hodgkin Disease

pentobarbital has been researched along with Hodgkin Disease in 1 studies

Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.

Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
KURZ, GH1

Other Studies

1 other study available for pentobarbital and Hodgkin Disease

ArticleYear
RETINOPATHY OF OBSCURE (TOXIC?) ORIGIN IN HODGKIN'S DISEASE.
    American journal of ophthalmology, 1964, Volume: 57

    Topics: Anemia; Chloramphenicol; Chlorpromazine; Eye; Glutethimide; Herpes Zoster; Herpes Zoster Ophthalmicu

1964